CatherineAnnShuMD

Hematologic Oncology, Thoracic Cancer

Physician

Overview of Dr. Shu

Dr. Catherine Shu is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital and NewYork-Presbyterian/Columbia University Irving Medical Center. She received her medical degree from Columbia University Vagelos College of Physicians and Surgeons and has been in practice 8 years. She is one of 375 doctors at New York-Presbyterian Hospital and one of 118 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Oncology. She has more than 30 publications and over 500 citings.

Office
177 Fort Washington Ave
# Milstein
New York, NY 10032
Book by Phone+1(951) 795-4273

Education & Training

New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2009 - 2012
Columbia University Vagelos College of Physicians and SurgeonsClass of 2009
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology
Princeton UniversityBSE

Certifications & Licensure

FL State Medical License 2021 - Present
NJ State Medical License 2022 - 2025
NY State Medical License 2010 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC Start of enrollment: 2016 Jun 07
Completed
Phase 2
SGI-110 Plus Durvalumab/Tremelimumab in SCLC Start of enrollment: 2017 Dec 15
Completed
Phase 1
Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment Start of enrollment: 2022 Dec 01
Withdrawn
Phase 2
Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation Start of enrollment: 2022 Dec 15
Recruiting
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

2 citations
Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases FromandOncogene-Driven Non-Small Cell Lung Cancer (TURBO-NSCLC).
Luke R G Pike, Emily Miao, Lillian A Boe, Tejas Patil, Brandon S Imber
Journal of Clinical Oncology. 2024-10-20
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve-Mutant Metastatic Non-Small Cell Lung...
Xiuning Le, Jyoti D Patel, Elaine Shum, Christina Baik, Rachel E Sanborn
Journal of Clinical Oncology. 2024-10-08
Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC.
Kaiwen Wang, Robyn Du, Nathaniel J Myall, Whitney E Lewis, Natalie Uy
Journal of Thoracic Oncology. 2024-03-01

Press Mentions

Lung Cancer Screening: Do Updated Criteria Address Racial Disparities?January 18th, 2022
Dr. Catherine Shu Discusses a Study with Important Implications in the Treatment of Lung CancerJanuary 17th, 2022
The CDC Launches a “Coronavirus Self-Checker” Bot Called Clara for People in the United StatesMarch 23rd, 2020
Join now to see all